Kathy P Willowson1,2, Geoffrey P Schembri1, Elizabeth J Bernard1, David Lh Chan1, Dale L Bailey3,4. 1. Department of Nuclear Medicine, Royal North Shore Hospital, St Leonards, NSW, 2065, Australia. 2. Institute of Medical Physics, School of Physics, The University of Sydney, Camperdown, NSW, 2006, Australia. 3. Department of Nuclear Medicine, Royal North Shore Hospital, St Leonards, NSW, 2065, Australia. Dale.Bailey@sydney.edu.au. 4. Discipline of Medical Imaging Science, Faculty of Health Sciences, The University of Sydney, Camperdown, NSW, 2006, Australia. Dale.Bailey@sydney.edu.au.
Abstract
PURPOSE: To quantify the effects of absorbed radiation dose on healthy liver parenchyma following radioembolisation (RE) using [99mTc]TcMebrofenin to analyse both global and regional liver function. METHODS: Patients having RE to treat hepatic disease underwent a [99mTc]TcMebrofenin hepatobilliary scintigraphy (HBS) study at both baseline and 8 weeks following treatment. Changes in global liver uptake rate were compared with healthy liver absorbed dose measures derived from the post-treatment 90Y PET/CT, including average dose, minimum dose to 70% of the volume (D70) and volume receiving at least 50 Gy (V50). Changes in functional burden associated with treatment and spared liver volumes in patients receiving lobar RE were also assessed, as were changes experienced by regional volumes corresponding to various dose ranges. Standard liver function pathology tests (LFTs) (bilirubin, albumin, ALP, AST, ALT and GGT) were examined for changes between baseline and post-treatment. RESULTS: Thirty-five patients were included in the study, of which, 9 had lobar treatment. A significant linear correlation was found between both baseline global liver uptake rate (negative) and D70 with change in global liver uptake rate. Patients undergoing lobar treatments demonstrated a shift in functional burden, and a significant difference was seen between the mean dose corresponding to liver volumes that increased their functional burden (9 Gy) and those that decreased their functional burden (35 Gy). No baseline LFTs predicted a decrease in global liver function; however, D70 demonstrated a linear correlation with changes in bilirubin and GGT. CONCLUSIONS: Given the significant negative relationship between baseline and change in global liver uptake rate, baseline HBS studies should not be used alone to disqualify patients considered for RE. In terms of treatment planning and evaluation, D70 may be the most appropriate metric of dose, with values greater than 15 Gy indicative of a likely drop in global liver function. The evidence of increasing functional burden in spared liver volumes suggests that patients at risk of complications could benefit from a lobar approach to treatment.
PURPOSE: To quantify the effects of absorbed radiation dose on healthy liver parenchyma following radioembolisation (RE) using [99mTc]TcMebrofenin to analyse both global and regional liver function. METHODS:Patients having RE to treat hepatic disease underwent a [99mTc]TcMebrofenin hepatobilliary scintigraphy (HBS) study at both baseline and 8 weeks following treatment. Changes in global liver uptake rate were compared with healthy liver absorbed dose measures derived from the post-treatment 90Y PET/CT, including average dose, minimum dose to 70% of the volume (D70) and volume receiving at least 50 Gy (V50). Changes in functional burden associated with treatment and spared liver volumes in patients receiving lobar RE were also assessed, as were changes experienced by regional volumes corresponding to various dose ranges. Standard liver function pathology tests (LFTs) (bilirubin, albumin, ALP, AST, ALT and GGT) were examined for changes between baseline and post-treatment. RESULTS: Thirty-five patients were included in the study, of which, 9 had lobar treatment. A significant linear correlation was found between both baseline global liver uptake rate (negative) and D70 with change in global liver uptake rate. Patients undergoing lobar treatments demonstrated a shift in functional burden, and a significant difference was seen between the mean dose corresponding to liver volumes that increased their functional burden (9 Gy) and those that decreased their functional burden (35 Gy). No baseline LFTs predicted a decrease in global liver function; however, D70 demonstrated a linear correlation with changes in bilirubin and GGT. CONCLUSIONS: Given the significant negative relationship between baseline and change in global liver uptake rate, baseline HBS studies should not be used alone to disqualify patients considered for RE. In terms of treatment planning and evaluation, D70 may be the most appropriate metric of dose, with values greater than 15 Gy indicative of a likely drop in global liver function. The evidence of increasing functional burden in spared liver volumes suggests that patients at risk of complications could benefit from a lobar approach to treatment.
Authors: Seza A Gulec; Manuel L Sztejnberg; Jeffry A Siegel; Tatjana Jevremovic; Michael Stabin Journal: J Nucl Med Date: 2010-01-15 Impact factor: 10.057
Authors: Belen Gil-Alzugaray; Ana Chopitea; Mercedes Iñarrairaegui; Jose I Bilbao; Macarena Rodriguez-Fraile; Javier Rodriguez; Alberto Benito; Inés Dominguez; Delia D'Avola; Jose I Herrero; Jorge Quiroga; Jesus Prieto; Bruno Sangro Journal: Hepatology Date: 2013-02-15 Impact factor: 17.425
Authors: C Chiesa; M Maccauro; R Romito; C Spreafico; S Pellizzari; A Negri; C Sposito; C Morosi; E Civelli; R Lanocita; T Camerini; C Bampo; S Bhoori; E Seregni; A Marchianò; V Mazzaferro; E Bombardieri Journal: Q J Nucl Med Mol Imaging Date: 2011-04 Impact factor: 2.346
Authors: Deha Erdogan; Bob H M Heijnen; Roelof J Bennink; Mariël Kok; Sander Dinant; Irene H Straatsburg; Dirk J Gouma; Thomas M van Gulik Journal: Liver Int Date: 2004-04 Impact factor: 5.828
Authors: T Chapelle; B Op de Beeck; A Driessen; G Roeyen; B Bracke; V Hartman; I Huyghe; S Morrison; D Ysebaert; S Francque Journal: Eur J Surg Oncol Date: 2017-09-04 Impact factor: 4.424
Authors: Roelof J Bennink; Kasia P Cieslak; Otto M van Delden; Krijn P van Lienden; Heinz-Josef Klümpen; Peter L Jansen; Thomas M van Gulik Journal: Front Oncol Date: 2014-06-16 Impact factor: 6.244
Authors: Manon N G J A Braat; Hugo W de Jong; Beatrijs A Seinstra; Mike V Scholten; Maurice A A J van den Bosch; Marnix G E H Lam Journal: EJNMMI Res Date: 2017-01-05 Impact factor: 3.138
Authors: Marta Cremonesi; Carlo Chiesa; Lidia Strigari; Mahila Ferrari; Francesca Botta; Francesco Guerriero; Concetta De Cicco; Guido Bonomo; Franco Orsi; Lisa Bodei; Amalia Di Dia; Chiara Maria Grana; Roberto Orecchia Journal: Front Oncol Date: 2014-08-19 Impact factor: 6.244